Dandekar Atul 4
4 · Maze Therapeutics, Inc. · Filed May 1, 2026
Research Summary
AI-generated summary of this filing
Maze Therapeutics CSBO Atul Dandekar Exercises Options, Sells 7,500 Shares
What Happened
Atul Dandekar, Maze Therapeutics (MAZE) Chief Strategy & Business Officer, exercised 7,500 stock options and immediately sold 7,500 shares on April 29, 2026. The exercise acquisition cost reported was $78,150 (7,500 shares × $10.42). The open-market sale generated gross proceeds of $190,299 (7,500 shares at a weighted average $25.37), yielding a pre-tax difference of about $112,149.
Key Details
- Transaction date: 2026-04-29; Form 4 filed: 2026-05-01 (timely filing).
- Exercise (code M): 7,500 shares acquired at $10.42 each — total $78,150. The option was fully vested (vested March 17, 2025).
- Sale (code S): 7,500 shares sold at a weighted average price of $25.37 — total proceeds $190,299. Sales prices in the block ranged from $25.08 to $25.77 per share.
- A separate line shows a disposition of 7,500 derivative units at $0, reflecting the derivative conversion/settlement associated with the exercise.
- Sale executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- Shares owned after the transactions are not specified in the provided excerpt of the filing.
Context
This was an exercise-and-sell (often called a cashless or immediate-sale) transaction: the insider exercised vested options and sold the resulting shares under a pre-established 10b5-1 plan. Such trades are typically pre-authorized and can be routine; they do not alone indicate management's forward-looking view of the company.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-04-29$10.42/sh+7,500$78,150→ 18,003 total - Sale
Common Stock
[F1][F2]2026-04-29$25.37/sh−7,500$190,299→ 10,503 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F3]2026-04-29−7,500→ 44,143 totalExercise: $10.42Exp: 2031-04-11→ Common Stock (7,500 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.08 to $25.77 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.